+ Watch LXRX
on My Watchlist
A biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease.
866M still seems like way to much cap for Lexicon, but it doesn't seem like much compared to the 1.5B cap the company briefly sported in August. Something is keeping the stock afloat and I can either play in the waves or resolutely hold a red thumb until the hot air finally escapes the balloon. I've seen hot air stocks like Opko and Star maintain disproportionate valuations for years, so I'll take a chance of getting swirled with a green thumb on Lexicon here. Phase III trials of telotristat in carcinoid syndrome and LX4211 in type II diabetes should keep some enthusiasm alive in 2013.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions